Public-Private Partnerships Vital to Advance Ebola Treatment Pipeline
In the battle against Ebola, incentives from governments and healthcare policymakers have been and will continue to be vital for advancing the current treatment pipeline, by mitigating the risk and up-front costs from pharmaceutical companies, says an analyst with research and consulting firm GlobalData.
Daian Cheng, PhD, GlobalData’s Analyst covering Infectious Diseases, states that despite a clear need for novel therapeutic approaches to combat Ebola, the infection has not represented an attractive investment for pharmaceutical companies due to its low incidence and the occurrence of outbreaks in countries that cannot afford expensive medicines.
Cheng says: “These two factors drastically reduce the ability of drug developers to recoup their R&D costs.
“So far, clinical-stage experimental treatments for Ebola have all been advanced, at least in part, with the financial support of public entities, and the contribution of public resources to R&D has only increased as fears of the virus have spread.”
Cheng notes that the most advanced Ebola pipeline candidate is GlaxoSmithKline’s (GSK) therapeutic vaccine, cAd3-ZEBOV. This treatment was originally developed jointly by the US National Institute of Allergy and Infectious Diseases and Okairos, which was acquired by GSK in 2013.
Cheng explains: “GSK’s vaccine contains a chimpanzee-derived adenovirus vector that carries a single Ebola viral gene and targets the Ebola Zaire strain, which is responsible for the current outbreak.
“A Phase I study in healthy UK volunteers started in September and the initial manufacturing costs are being supported by a recently formed international consortium of government bodies and leading research institutions. This is headlined by a joint $4.5 million grant from the Wellcome Trust, the Medical Research Council, and the UK Department for International Development."
The analyst adds that experts are hopeful for data on cAd3-ZEBOV’s safety and dosing in healthy volunteers to be available by the end of this year. Other pharmaceutical companies with promising Ebola treatments that are partially supported by public funding include Johnson & Johnson, Mapp Biopharmaceutical, and NewLink Genetics.
“Ultimately, more partnerships between public entities and pharmaceutical companies are needed to bring to market novel therapies that combat neglected diseases, particularly those which, like Ebola, affect resource-deprived regions of the world,” Cheng concludes.
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance